ACLY and ovarian cancer: Finally, intersection with drug resistance-associated genes was reported in the review of Yang et al. (ACLY, ACACA, ACACB, FASN, CPT1A, CPT1B, CPT1C, CPT2, SCD), confirming ACACA, FASN, CPT2 and SCD as LRGs that function synergistically with CPT1A in the occurrence of paclitaxel resistance in ovarian cancer.